Loading…
Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation
Objective. The expression of NILCO molecules (Notch, IL-1, and leptin crosstalk outcome) and the association with obesity were investigated in types I and II endometrial cancer (EmCa). Additionally, the involvement of NILCO in leptin-induced invasiveness of EmCa cells was investigated. Methods. The...
Saved in:
Published in: | Disease markers 2017-01, Vol.2017 (2017), p.1-14 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3 |
---|---|
cites | cdi_FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3 |
container_end_page | 14 |
container_issue | 2017 |
container_start_page | 1 |
container_title | Disease markers |
container_volume | 2017 |
creator | Gonzalez-Perez, Ruben Rene Pattillo, Roland Candelaria, Pierre V. Lee, Regina Lanier, Viola Vann, Kiara T. Oprea-Ilies, Gabriela Daley-Brown, Danielle Quarshie, Alexander |
description | Objective. The expression of NILCO molecules (Notch, IL-1, and leptin crosstalk outcome) and the association with obesity were investigated in types I and II endometrial cancer (EmCa). Additionally, the involvement of NILCO in leptin-induced invasiveness of EmCa cells was investigated. Methods. The expression of NILCO mRNAs and proteins were analyzed in EmCa from African-American n=29 and Chinese patients (tissue array, n=120 cases). The role of NILCO in leptin-induced invasion of Ishikawa and An3ca EmCa cells was investigated using Notch, IL-1, and leptin signaling inhibitors. Results. NILCO molecules were expressed higher in type II EmCa, regardless of ethnic background or obesity status of patients. NILCO proteins were mainly localized in the cellular membrane and cytoplasm of type II EmCa. Additionally, EmCa from obese African-American patients showed higher levels of NILCO molecules than EmCa from lean patients. Notably, leptin-induced EmCa cell invasion was abrogated by NILCO inhibitors. Conclusion. Type II EmCa expressed higher NILCO molecules, which may suggest it is involved in the progression of the more aggressive EmCa phenotype. Obesity was associated with higher expression of NILCO molecules in EmCa. Leptin-induced cell invasion was dependent on NILCO. Hence, NILCO might be involved in tumor progression and could represent a new target/biomarker for type II EmCa. |
doi_str_mv | 10.1155/2017/8248175 |
format | article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5474242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A550015085</galeid><sourcerecordid>A550015085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3</originalsourceid><addsrcrecordid>eNqNkcFP2zAUxq2JCTrgtvMUicukLWA7dmzvMKmqOqhU0R3Y2XKSFzBK7GIn3fjv56oFNk6c_CT_9L3vex9CHwk-J4TzC4qJuJCUSSL4OzQhUvBclgU-QBNMhcwxZfgIfYjxHmNCFVOH6IjKkquSlxN0dfO4hmyxyOau8T0MwZoumxlXQ8hWGwjwZx0gRojZ9WI5W33LptnPAJ3trTPhMZtvTDeawXp3gt63potwun-P0a8f85vZVb5cXS5m02VeM6WGPJmpQFSqYpQqzkkyTihlaWoZZQKaFigtDS9UUbEaWMOxZEUrKsEMCKiKY_R9p7seqx6aGtwQTKfXwfbJkPbG6v9_nL3Tt36jORNpA00Cn_cCwT-MEAfd21hD1xkHfoyaKMIkK4UsEnr2Cr33Y3Apnk5Xx1JQJfELdWs60Na1Pu2tt6J6ynk6eorAE_V1R9XBxxigfbZMsN4WuZUUel9kwj_9G_MZfmouAV92wJ11jflt3ygHiYHWvNCEU17Q4i-E9KxV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2010872980</pqid></control><display><type>article</type><title>Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation</title><source>Wiley Open Access</source><creator>Gonzalez-Perez, Ruben Rene ; Pattillo, Roland ; Candelaria, Pierre V. ; Lee, Regina ; Lanier, Viola ; Vann, Kiara T. ; Oprea-Ilies, Gabriela ; Daley-Brown, Danielle ; Quarshie, Alexander</creator><contributor>Singer, Eric A. ; Eric A Singer</contributor><creatorcontrib>Gonzalez-Perez, Ruben Rene ; Pattillo, Roland ; Candelaria, Pierre V. ; Lee, Regina ; Lanier, Viola ; Vann, Kiara T. ; Oprea-Ilies, Gabriela ; Daley-Brown, Danielle ; Quarshie, Alexander ; Singer, Eric A. ; Eric A Singer</creatorcontrib><description>Objective. The expression of NILCO molecules (Notch, IL-1, and leptin crosstalk outcome) and the association with obesity were investigated in types I and II endometrial cancer (EmCa). Additionally, the involvement of NILCO in leptin-induced invasiveness of EmCa cells was investigated. Methods. The expression of NILCO mRNAs and proteins were analyzed in EmCa from African-American n=29 and Chinese patients (tissue array, n=120 cases). The role of NILCO in leptin-induced invasion of Ishikawa and An3ca EmCa cells was investigated using Notch, IL-1, and leptin signaling inhibitors. Results. NILCO molecules were expressed higher in type II EmCa, regardless of ethnic background or obesity status of patients. NILCO proteins were mainly localized in the cellular membrane and cytoplasm of type II EmCa. Additionally, EmCa from obese African-American patients showed higher levels of NILCO molecules than EmCa from lean patients. Notably, leptin-induced EmCa cell invasion was abrogated by NILCO inhibitors. Conclusion. Type II EmCa expressed higher NILCO molecules, which may suggest it is involved in the progression of the more aggressive EmCa phenotype. Obesity was associated with higher expression of NILCO molecules in EmCa. Leptin-induced cell invasion was dependent on NILCO. Hence, NILCO might be involved in tumor progression and could represent a new target/biomarker for type II EmCa.</description><identifier>ISSN: 0278-0240</identifier><identifier>ISSN: 1875-8630</identifier><identifier>EISSN: 1875-8630</identifier><identifier>DOI: 10.1155/2017/8248175</identifier><identifier>PMID: 28659656</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Adenocarcinoma, Papillary - complications ; Adenocarcinoma, Papillary - diagnosis ; Adenocarcinoma, Papillary - ethnology ; Adenocarcinoma, Papillary - genetics ; Aged ; Antibodies - pharmacology ; Asian People ; Biological markers ; Biomarkers ; Black or African American ; Black People ; Cancer ; Carcinoma, Endometrioid - complications ; Carcinoma, Endometrioid - diagnosis ; Carcinoma, Endometrioid - ethnology ; Carcinoma, Endometrioid - genetics ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Crosstalk ; Cystadenocarcinoma, Serous - complications ; Cystadenocarcinoma, Serous - diagnosis ; Cystadenocarcinoma, Serous - ethnology ; Cystadenocarcinoma, Serous - genetics ; Cytoplasm ; Development and progression ; Diamines - pharmacology ; Disease Progression ; Endometrial cancer ; Endometrial Neoplasms - complications ; Endometrial Neoplasms - diagnosis ; Endometrial Neoplasms - ethnology ; Endometrial Neoplasms - genetics ; Endometrium ; Endometrium - metabolism ; Endometrium - pathology ; Female ; Gene expression ; Gene Expression Regulation, Neoplastic ; Genetic aspects ; Humans ; Inhibitors ; Interleukin 1 ; Interleukin-1 - antagonists & inhibitors ; Interleukin-1 - genetics ; Interleukin-1 - metabolism ; Invasiveness ; Leptin ; Leptin - genetics ; Leptin - metabolism ; Middle Aged ; Neoplasm Staging ; Obesity ; Obesity - complications ; Obesity - diagnosis ; Obesity - ethnology ; Obesity - genetics ; Patients ; Phenotypes ; Protein Isoforms - antagonists & inhibitors ; Protein Isoforms - genetics ; Protein Isoforms - metabolism ; Proteins ; Receptor, Notch1 - antagonists & inhibitors ; Receptor, Notch1 - genetics ; Receptor, Notch1 - metabolism ; Signal Transduction ; Signaling ; Thiazoles - pharmacology</subject><ispartof>Disease markers, 2017-01, Vol.2017 (2017), p.1-14</ispartof><rights>Copyright © 2017 Danielle Daley-Brown et al.</rights><rights>COPYRIGHT 2017 John Wiley & Sons, Inc.</rights><rights>Copyright © 2017 Danielle Daley-Brown et al.; This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2017 Danielle Daley-Brown et al. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3</citedby><cites>FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3</cites><orcidid>0000-0001-8922-6011 ; 0000-0002-2542-0111 ; 0000-0002-0096-8391 ; 0000-0001-9197-7172 ; 0000-0003-3447-5525</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28659656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Singer, Eric A.</contributor><contributor>Eric A Singer</contributor><creatorcontrib>Gonzalez-Perez, Ruben Rene</creatorcontrib><creatorcontrib>Pattillo, Roland</creatorcontrib><creatorcontrib>Candelaria, Pierre V.</creatorcontrib><creatorcontrib>Lee, Regina</creatorcontrib><creatorcontrib>Lanier, Viola</creatorcontrib><creatorcontrib>Vann, Kiara T.</creatorcontrib><creatorcontrib>Oprea-Ilies, Gabriela</creatorcontrib><creatorcontrib>Daley-Brown, Danielle</creatorcontrib><creatorcontrib>Quarshie, Alexander</creatorcontrib><title>Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation</title><title>Disease markers</title><addtitle>Dis Markers</addtitle><description>Objective. The expression of NILCO molecules (Notch, IL-1, and leptin crosstalk outcome) and the association with obesity were investigated in types I and II endometrial cancer (EmCa). Additionally, the involvement of NILCO in leptin-induced invasiveness of EmCa cells was investigated. Methods. The expression of NILCO mRNAs and proteins were analyzed in EmCa from African-American n=29 and Chinese patients (tissue array, n=120 cases). The role of NILCO in leptin-induced invasion of Ishikawa and An3ca EmCa cells was investigated using Notch, IL-1, and leptin signaling inhibitors. Results. NILCO molecules were expressed higher in type II EmCa, regardless of ethnic background or obesity status of patients. NILCO proteins were mainly localized in the cellular membrane and cytoplasm of type II EmCa. Additionally, EmCa from obese African-American patients showed higher levels of NILCO molecules than EmCa from lean patients. Notably, leptin-induced EmCa cell invasion was abrogated by NILCO inhibitors. Conclusion. Type II EmCa expressed higher NILCO molecules, which may suggest it is involved in the progression of the more aggressive EmCa phenotype. Obesity was associated with higher expression of NILCO molecules in EmCa. Leptin-induced cell invasion was dependent on NILCO. Hence, NILCO might be involved in tumor progression and could represent a new target/biomarker for type II EmCa.</description><subject>Adenocarcinoma, Papillary - complications</subject><subject>Adenocarcinoma, Papillary - diagnosis</subject><subject>Adenocarcinoma, Papillary - ethnology</subject><subject>Adenocarcinoma, Papillary - genetics</subject><subject>Aged</subject><subject>Antibodies - pharmacology</subject><subject>Asian People</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Black or African American</subject><subject>Black People</subject><subject>Cancer</subject><subject>Carcinoma, Endometrioid - complications</subject><subject>Carcinoma, Endometrioid - diagnosis</subject><subject>Carcinoma, Endometrioid - ethnology</subject><subject>Carcinoma, Endometrioid - genetics</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Crosstalk</subject><subject>Cystadenocarcinoma, Serous - complications</subject><subject>Cystadenocarcinoma, Serous - diagnosis</subject><subject>Cystadenocarcinoma, Serous - ethnology</subject><subject>Cystadenocarcinoma, Serous - genetics</subject><subject>Cytoplasm</subject><subject>Development and progression</subject><subject>Diamines - pharmacology</subject><subject>Disease Progression</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - complications</subject><subject>Endometrial Neoplasms - diagnosis</subject><subject>Endometrial Neoplasms - ethnology</subject><subject>Endometrial Neoplasms - genetics</subject><subject>Endometrium</subject><subject>Endometrium - metabolism</subject><subject>Endometrium - pathology</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genetic aspects</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Interleukin 1</subject><subject>Interleukin-1 - antagonists & inhibitors</subject><subject>Interleukin-1 - genetics</subject><subject>Interleukin-1 - metabolism</subject><subject>Invasiveness</subject><subject>Leptin</subject><subject>Leptin - genetics</subject><subject>Leptin - metabolism</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - diagnosis</subject><subject>Obesity - ethnology</subject><subject>Obesity - genetics</subject><subject>Patients</subject><subject>Phenotypes</subject><subject>Protein Isoforms - antagonists & inhibitors</subject><subject>Protein Isoforms - genetics</subject><subject>Protein Isoforms - metabolism</subject><subject>Proteins</subject><subject>Receptor, Notch1 - antagonists & inhibitors</subject><subject>Receptor, Notch1 - genetics</subject><subject>Receptor, Notch1 - metabolism</subject><subject>Signal Transduction</subject><subject>Signaling</subject><subject>Thiazoles - pharmacology</subject><issn>0278-0240</issn><issn>1875-8630</issn><issn>1875-8630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNkcFP2zAUxq2JCTrgtvMUicukLWA7dmzvMKmqOqhU0R3Y2XKSFzBK7GIn3fjv56oFNk6c_CT_9L3vex9CHwk-J4TzC4qJuJCUSSL4OzQhUvBclgU-QBNMhcwxZfgIfYjxHmNCFVOH6IjKkquSlxN0dfO4hmyxyOau8T0MwZoumxlXQ8hWGwjwZx0gRojZ9WI5W33LptnPAJ3trTPhMZtvTDeawXp3gt63potwun-P0a8f85vZVb5cXS5m02VeM6WGPJmpQFSqYpQqzkkyTihlaWoZZQKaFigtDS9UUbEaWMOxZEUrKsEMCKiKY_R9p7seqx6aGtwQTKfXwfbJkPbG6v9_nL3Tt36jORNpA00Cn_cCwT-MEAfd21hD1xkHfoyaKMIkK4UsEnr2Cr33Y3Apnk5Xx1JQJfELdWs60Na1Pu2tt6J6ynk6eorAE_V1R9XBxxigfbZMsN4WuZUUel9kwj_9G_MZfmouAV92wJ11jflt3ygHiYHWvNCEU17Q4i-E9KxV</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Gonzalez-Perez, Ruben Rene</creator><creator>Pattillo, Roland</creator><creator>Candelaria, Pierre V.</creator><creator>Lee, Regina</creator><creator>Lanier, Viola</creator><creator>Vann, Kiara T.</creator><creator>Oprea-Ilies, Gabriela</creator><creator>Daley-Brown, Danielle</creator><creator>Quarshie, Alexander</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8922-6011</orcidid><orcidid>https://orcid.org/0000-0002-2542-0111</orcidid><orcidid>https://orcid.org/0000-0002-0096-8391</orcidid><orcidid>https://orcid.org/0000-0001-9197-7172</orcidid><orcidid>https://orcid.org/0000-0003-3447-5525</orcidid></search><sort><creationdate>20170101</creationdate><title>Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation</title><author>Gonzalez-Perez, Ruben Rene ; Pattillo, Roland ; Candelaria, Pierre V. ; Lee, Regina ; Lanier, Viola ; Vann, Kiara T. ; Oprea-Ilies, Gabriela ; Daley-Brown, Danielle ; Quarshie, Alexander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adenocarcinoma, Papillary - complications</topic><topic>Adenocarcinoma, Papillary - diagnosis</topic><topic>Adenocarcinoma, Papillary - ethnology</topic><topic>Adenocarcinoma, Papillary - genetics</topic><topic>Aged</topic><topic>Antibodies - pharmacology</topic><topic>Asian People</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Black or African American</topic><topic>Black People</topic><topic>Cancer</topic><topic>Carcinoma, Endometrioid - complications</topic><topic>Carcinoma, Endometrioid - diagnosis</topic><topic>Carcinoma, Endometrioid - ethnology</topic><topic>Carcinoma, Endometrioid - genetics</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Crosstalk</topic><topic>Cystadenocarcinoma, Serous - complications</topic><topic>Cystadenocarcinoma, Serous - diagnosis</topic><topic>Cystadenocarcinoma, Serous - ethnology</topic><topic>Cystadenocarcinoma, Serous - genetics</topic><topic>Cytoplasm</topic><topic>Development and progression</topic><topic>Diamines - pharmacology</topic><topic>Disease Progression</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - complications</topic><topic>Endometrial Neoplasms - diagnosis</topic><topic>Endometrial Neoplasms - ethnology</topic><topic>Endometrial Neoplasms - genetics</topic><topic>Endometrium</topic><topic>Endometrium - metabolism</topic><topic>Endometrium - pathology</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genetic aspects</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Interleukin 1</topic><topic>Interleukin-1 - antagonists & inhibitors</topic><topic>Interleukin-1 - genetics</topic><topic>Interleukin-1 - metabolism</topic><topic>Invasiveness</topic><topic>Leptin</topic><topic>Leptin - genetics</topic><topic>Leptin - metabolism</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - diagnosis</topic><topic>Obesity - ethnology</topic><topic>Obesity - genetics</topic><topic>Patients</topic><topic>Phenotypes</topic><topic>Protein Isoforms - antagonists & inhibitors</topic><topic>Protein Isoforms - genetics</topic><topic>Protein Isoforms - metabolism</topic><topic>Proteins</topic><topic>Receptor, Notch1 - antagonists & inhibitors</topic><topic>Receptor, Notch1 - genetics</topic><topic>Receptor, Notch1 - metabolism</topic><topic>Signal Transduction</topic><topic>Signaling</topic><topic>Thiazoles - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzalez-Perez, Ruben Rene</creatorcontrib><creatorcontrib>Pattillo, Roland</creatorcontrib><creatorcontrib>Candelaria, Pierre V.</creatorcontrib><creatorcontrib>Lee, Regina</creatorcontrib><creatorcontrib>Lanier, Viola</creatorcontrib><creatorcontrib>Vann, Kiara T.</creatorcontrib><creatorcontrib>Oprea-Ilies, Gabriela</creatorcontrib><creatorcontrib>Daley-Brown, Danielle</creatorcontrib><creatorcontrib>Quarshie, Alexander</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzalez-Perez, Ruben Rene</au><au>Pattillo, Roland</au><au>Candelaria, Pierre V.</au><au>Lee, Regina</au><au>Lanier, Viola</au><au>Vann, Kiara T.</au><au>Oprea-Ilies, Gabriela</au><au>Daley-Brown, Danielle</au><au>Quarshie, Alexander</au><au>Singer, Eric A.</au><au>Eric A Singer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation</atitle><jtitle>Disease markers</jtitle><addtitle>Dis Markers</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>2017</volume><issue>2017</issue><spage>1</spage><epage>14</epage><pages>1-14</pages><issn>0278-0240</issn><issn>1875-8630</issn><eissn>1875-8630</eissn><abstract>Objective. The expression of NILCO molecules (Notch, IL-1, and leptin crosstalk outcome) and the association with obesity were investigated in types I and II endometrial cancer (EmCa). Additionally, the involvement of NILCO in leptin-induced invasiveness of EmCa cells was investigated. Methods. The expression of NILCO mRNAs and proteins were analyzed in EmCa from African-American n=29 and Chinese patients (tissue array, n=120 cases). The role of NILCO in leptin-induced invasion of Ishikawa and An3ca EmCa cells was investigated using Notch, IL-1, and leptin signaling inhibitors. Results. NILCO molecules were expressed higher in type II EmCa, regardless of ethnic background or obesity status of patients. NILCO proteins were mainly localized in the cellular membrane and cytoplasm of type II EmCa. Additionally, EmCa from obese African-American patients showed higher levels of NILCO molecules than EmCa from lean patients. Notably, leptin-induced EmCa cell invasion was abrogated by NILCO inhibitors. Conclusion. Type II EmCa expressed higher NILCO molecules, which may suggest it is involved in the progression of the more aggressive EmCa phenotype. Obesity was associated with higher expression of NILCO molecules in EmCa. Leptin-induced cell invasion was dependent on NILCO. Hence, NILCO might be involved in tumor progression and could represent a new target/biomarker for type II EmCa.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>28659656</pmid><doi>10.1155/2017/8248175</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0001-8922-6011</orcidid><orcidid>https://orcid.org/0000-0002-2542-0111</orcidid><orcidid>https://orcid.org/0000-0002-0096-8391</orcidid><orcidid>https://orcid.org/0000-0001-9197-7172</orcidid><orcidid>https://orcid.org/0000-0003-3447-5525</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0278-0240 |
ispartof | Disease markers, 2017-01, Vol.2017 (2017), p.1-14 |
issn | 0278-0240 1875-8630 1875-8630 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5474242 |
source | Wiley Open Access |
subjects | Adenocarcinoma, Papillary - complications Adenocarcinoma, Papillary - diagnosis Adenocarcinoma, Papillary - ethnology Adenocarcinoma, Papillary - genetics Aged Antibodies - pharmacology Asian People Biological markers Biomarkers Black or African American Black People Cancer Carcinoma, Endometrioid - complications Carcinoma, Endometrioid - diagnosis Carcinoma, Endometrioid - ethnology Carcinoma, Endometrioid - genetics Cell Line, Tumor Cell Proliferation - drug effects Crosstalk Cystadenocarcinoma, Serous - complications Cystadenocarcinoma, Serous - diagnosis Cystadenocarcinoma, Serous - ethnology Cystadenocarcinoma, Serous - genetics Cytoplasm Development and progression Diamines - pharmacology Disease Progression Endometrial cancer Endometrial Neoplasms - complications Endometrial Neoplasms - diagnosis Endometrial Neoplasms - ethnology Endometrial Neoplasms - genetics Endometrium Endometrium - metabolism Endometrium - pathology Female Gene expression Gene Expression Regulation, Neoplastic Genetic aspects Humans Inhibitors Interleukin 1 Interleukin-1 - antagonists & inhibitors Interleukin-1 - genetics Interleukin-1 - metabolism Invasiveness Leptin Leptin - genetics Leptin - metabolism Middle Aged Neoplasm Staging Obesity Obesity - complications Obesity - diagnosis Obesity - ethnology Obesity - genetics Patients Phenotypes Protein Isoforms - antagonists & inhibitors Protein Isoforms - genetics Protein Isoforms - metabolism Proteins Receptor, Notch1 - antagonists & inhibitors Receptor, Notch1 - genetics Receptor, Notch1 - metabolism Signal Transduction Signaling Thiazoles - pharmacology |
title | Type II Endometrial Cancer Overexpresses NILCO: A Preliminary Evaluation |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T00%3A37%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Type%20II%20Endometrial%20Cancer%20Overexpresses%20NILCO:%20A%20Preliminary%20Evaluation&rft.jtitle=Disease%20markers&rft.au=Gonzalez-Perez,%20Ruben%20Rene&rft.date=2017-01-01&rft.volume=2017&rft.issue=2017&rft.spage=1&rft.epage=14&rft.pages=1-14&rft.issn=0278-0240&rft.eissn=1875-8630&rft_id=info:doi/10.1155/2017/8248175&rft_dat=%3Cgale_pubme%3EA550015085%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c499t-240be7b9b42295518241224551f4247edfe226a5393b4ce4d50843f7b74ae7eb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2010872980&rft_id=info:pmid/28659656&rft_galeid=A550015085&rfr_iscdi=true |